Kurlinkus, B.; Ger, M.; Kaupinis, A.; Jasiunas, E.; Valius, M.; Sileikis, A.
CEACAM6’s Role as a Chemoresistance and Prognostic Biomarker for Pancreatic Cancer: A Comparison of CEACAM6’s Diagnostic and Prognostic Capabilities with Those of CA19-9 and CEA. Life 2021, 11, 542.
https://doi.org/10.3390/life11060542
AMA Style
Kurlinkus B, Ger M, Kaupinis A, Jasiunas E, Valius M, Sileikis A.
CEACAM6’s Role as a Chemoresistance and Prognostic Biomarker for Pancreatic Cancer: A Comparison of CEACAM6’s Diagnostic and Prognostic Capabilities with Those of CA19-9 and CEA. Life. 2021; 11(6):542.
https://doi.org/10.3390/life11060542
Chicago/Turabian Style
Kurlinkus, Benediktas, Marija Ger, Algirdas Kaupinis, Eugenijus Jasiunas, Mindaugas Valius, and Audrius Sileikis.
2021. "CEACAM6’s Role as a Chemoresistance and Prognostic Biomarker for Pancreatic Cancer: A Comparison of CEACAM6’s Diagnostic and Prognostic Capabilities with Those of CA19-9 and CEA" Life 11, no. 6: 542.
https://doi.org/10.3390/life11060542
APA Style
Kurlinkus, B., Ger, M., Kaupinis, A., Jasiunas, E., Valius, M., & Sileikis, A.
(2021). CEACAM6’s Role as a Chemoresistance and Prognostic Biomarker for Pancreatic Cancer: A Comparison of CEACAM6’s Diagnostic and Prognostic Capabilities with Those of CA19-9 and CEA. Life, 11(6), 542.
https://doi.org/10.3390/life11060542